Two British Columbian cannabis producers have agreed to a new shared cultivation deal that will allow for the production of dried flower in the thousands of kilograms.

After the markets closed on Tuesday (October 22), Zenabis Global (TSX:ZENA) and privately held cannabis producer Tantalus Labs announced the deal, which is for an unspecified amount of cannabis production. No other details, such as compensation or breaking fees, were given.

The plants will be grown and harvested at Zenabis’ Langley, British Columbia, facility. Later, the Tantalus Labs team will take care of drying, trimming and packaging the resulting product.

Tantalus Labs’ methods and growing style will be used for specific segments of marijuana at Zenabis’ operation. These plants will originate from genetic material from Tantalus Labs.

Andrew Grieve, CEO of Zenabis, said he is pleased his company was picked for this partnership with a company known for its “meticulous approach” at growing.

“We share Tantalus Labs’ commitment to continuously push growing practices and standards onward and upward for the efficient production of high-quality, sungrown cannabis,” Grieve said.

Shares of Zenabis dropped sharply as the markets opened on Wednesday (October 23). The company had seen a decline of 7 percent by 10:32 a.m. EDT, resulting in a price per share of C$0.46. Eventually, trading settled for the company and it closed the day with only a 2 percent drop for a price of C$0.49.

Tuesday’s release indicates that the cultivation agreement’s initial term will be two years, with growing and supply taking place in 2020 and 2021.

Tantalus Labs CEO Dan Sutton shared excitement for the possibilities of this new partnership.

“This relationship will allow Tantalus to deliver our sungrown quality promise to an expanding audience in Canada, while collaborating with some of the brightest agricultural minds in this new Canadian cannabis industry,” Sutton said.

Zenabis faces stock market hardship

The share price drop for Zenabis continues a negative trend for the company this week. On Monday (October 21), the firm was forced to adjust development plans for its expansion in Langley, the same facility that the Tantalus Labs deal relates to.

Zenabis informed investors it will split its expansion plans into two phases, Zenabis Langley — Part 2B and Zenabis Langley — Part 2C, and it will also delay the new second stage of this expansion.

This delay was met with a drop in value for the British Columbian cannabis producer. Over a year-to-date period, shares of Zenabis have declined 92.25 percent, representing a loss per share of C$5.53.

“By early in the first quarter of 2020, we expect to have 111,200 kilograms of capacity licensed and operational with the approval of the Zenabis Langley — Part 2B amendment,” Grieve said.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the appointment of Mr. Al Reese, Jr., to its Board of Directors

Mr. Reese has over 40 years experience in public and private businesses including as CFO of a formerly Nasdaq-listed energy company where he arranged finance transactions totaling over $10 billion dollars during his 20-year tenure. Mr. Reese was a Director and Chairman of the Audit Committee of a community bank in Texas for ten years until such time as it was acquired by a larger banking group in 2018.

Keep reading... Show less

Mexico looks to be closer than ever to cannabis reform, with the country releasing its regulation plans to make the drug legal in medical settings.

Meanwhile, despite the financial hardships seen recently in the Canadian cannabis market, CEOs in the country are still receiving top dollar, as per a new study.

Keep reading... Show less

Not for Distribution to United States Newswire Services or for Dissemination in the United States

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today the pricing of its previously announced best efforts overnight marketed offering (the “Offering”) of subordinate voting shares (the “Offered Securities”) of the Company at a price of C$16.00 per share for a total gross proceeds of approximately US$125 Million. The issue price represents a 3.3% discount to the last close of the Company’s subordinate voting shares traded on the Canadian Securities Exchange as of January 14, 2021. 100% of the Offering is expected to be purchased by a total of seven new and existing institutional investors, including current shareholder, Wasatch Global Investors.

Keep reading... Show less

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Tilray, Inc. (NASDAQ: TLRY), Icanic Brands (OTC: ICNAF) (CSE: ICAN) Red Light Holland (OTC: TRUFF) (CSE: TRIP) and Aphria, Inc. (NASDAQ: APHA).

Investors are cheering new and expected legislation which is opening new market opportunities for both cannabis and psychedelics globally. Innovation in premium branding, growing technologies, manufacturing, with operational execution are key, in the drive towards profitability. Wall Street Reporter highlights the latest comments from industry thought leaders in cannabis and psychedelics:

Keep reading... Show less

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company”) today announced the closing of its previously announced underwritten public offering (the “Offering”) of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of $5.25 per unit (all prices in US$). The warrants have an exercise price of $6.58 per share, are immediately exercisable and will expire five years following the date of issuance. In connection with the Offering, the underwriter exercised in full its option to purchase an additional 274,285 shares of common stock and additional warrants to purchase 274,285 shares of common stock. The gross proceeds from the Offering were approximately $11.04 million, before deducting underwriting discounts and estimated offering expenses. No securities were offered or sold in Canada, including through the CSE or any other trading market in Canada

H.C. Wainwright & Co. (“Wainwright”) acted as the sole book-running manager for the Offering and is a non-related party to the Company.

Keep reading... Show less